Peripheral Artery Disease: Atherogenic Burden and Vascular Risk

It’s a blood-based risk scan for the processes that narrow leg arteries: cholesterol particle burden and vascular inflammation. These tests don’t diagnose PAD by themselves; they quantify the biology that drives plaque formation (atherosclerosis). Superpower measures LDL cholesterol, ApoB (total atherogenic particles), Lp(a) (genetically driven, pro-atherogenic/prothrombotic lipoprotein), hs-CRP (systemic inflammation), and AIP, the atherogenic index of plasma [log(triglycerides/HDL-C)] reflecting small, dense LDL. Together, they illuminate your arterial “supply chain” stress, complementing ankle–brachial index (ABI) or imaging. In plain terms, this blood panel tells you how much plaque-building pressure and inflammation your arteries are under, so you can track vascular risk over time with objective numbers.

PAD is a manifestation of whole‑body atherosclerosis. Blood biomarkers reveal the upstream forces—particle burden (LDL, ApoB, Lp[a]), inflammatory tone (hs‑CRP), and lipoprotein quality (AIP)—that cause plaque to develop and become unstable. Testing helps identify risk before symptoms like calf pain or non‑healing wounds appear, and it refines your overall cardiovascular risk beyond standard cholesterol. Results can be trended to confirm risk is moving in the right direction and to align with other PAD assessments such as ABI or duplex ultrasound. In short, this testing quantifies the biology of arterial disease so you know where you stand and what to monitor next.

Yes. With Superpower, our team member can organize a professional venous blood draw in your home, an optional add-on for $119. We bring the supplies, collect samples under clinical protocols, and deliver them to accredited laboratories for analysis of LDL, ApoB, Lp(a), hs‑CRP, and AIP. You get the same laboratory‑grade results you’d receive in a clinic, without leaving home. This supports consistent timing and conditions, which improves result comparability over time. It also streamlines follow‑up testing, so you can trend your vascular risk with minimal disruption to your routine.

Get a baseline, then retest at least annually to track direction. If you’re adjusting factors that influence lipids or inflammation, recheck in about 8–12 weeks to see a new steady state, then space to every 6–12 months. Lp(a) is largely genetic and usually needs measuring once for status confirmation. hs‑CRP can fluctuate with illness; confirm unexpected highs with a repeat 2–3 weeks later when well. The goal is stable, periodic measurements that show trajectory, not single snapshots. Align blood testing with any ABI or imaging follow‑up to connect biology with vessel measurements.

LDL and ApoB reflect the number of atherogenic particles; they shift with genetics, metabolic state, thyroid function, kidney/liver disease, and lipid‑lowering medications. Lp(a) is mostly genetically determined and stable; it can rise with significant inflammation or kidney disease. hs‑CRP rises with infections, injuries, chronic inflammatory conditions, and hard exercise; it falls as inflammation resolves. AIP depends on triglycerides and HDL; meals, alcohol, recent intense exercise, insulin resistance, and some hormones/medications can change it acutely. Illness, pregnancy, and circadian timing also matter. Consistent testing conditions reduce noise and make trends more meaningful.

For the most consistent AIP and triglycerides, fast 8–12 hours; water is fine. Avoid alcohol and unusually hard exercise for 24 hours. If you have a fever, active infection, or recent injury, delay hs‑CRP testing until you’re well for a stable baseline. Take your usual medications unless you’ve been told otherwise. Aim to test at a similar time of day across visits. Lp(a) and ApoB do not require fasting, but collecting them with the same prep improves comparability. Tell us about recent illness or major changes so we can interpret transient shifts appropriately.

Yes. LDL, ApoB, and AIP track the balance of lipid production, clearance, and particle remodeling, which respond over weeks to changes in weight, nutrition, activity patterns, sleep, and metabolic health. hs‑CRP reflects systemic inflammatory tone and typically declines as inflammation resolves. Lp(a) is largely fixed by genetics and usually changes little, though significant kidney disease or inflammation can shift it. Because these biomarkers move on different timelines, trends over several months provide a clearer picture than single results. Repeating measurements at steady intervals shows whether arterial risk pressure is easing or intensifying.

Lower LDL and ApoB indicate fewer atherogenic particles; for high‑risk vascular prevention, ApoB below ~80 mg/dL is often targeted, with lower being better. Lp(a) at or above 50 mg/dL (≈125 nmol/L) heightens atherosclerotic and thrombotic risk. hs‑CRP below 1.0 mg/L suggests low inflammatory risk, 1.0–3.0 mg/L average, and above 3.0 mg/L high (repeat when well if elevated). AIP, calculated as log10(triglycerides/HDL‑C), is low risk below 0.11, intermediate 0.11–0.21, and high above 0.21. Consider the pattern, not a single number: lower ApoB/LDL, low hs‑CRP, low AIP, and normal Lp(a) together indicate lower PAD biology pressure.